These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21550404)

  • 21. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.
    Yogalingam G; Pollard T; Gliddon B; Jolly RD; Hopwood JJ
    Genomics; 2002 Feb; 79(2):150-3. PubMed ID: 11829484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice.
    Lau AA; Hannouche H; Rozaklis T; Hassiotis S; Hopwood JJ; Hemsley KM
    Exp Neurol; 2010 Oct; 225(2):445-54. PubMed ID: 20673764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
    Yogalingam G; Hopwood JJ
    Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.
    King B; Setford ML; Hassiotis S; Trim PJ; Duplock S; Tucker JN; Hattersley K; Snel MF; Hopwood JJ; Hemsley KM
    Exp Neurol; 2016 Apr; 278():11-21. PubMed ID: 26626972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain.
    Beard H; Hassiotis S; Luck AJ; Rozaklis T; Hopwood JJ; Hemsley KM
    JIMD Rep; 2016; 29():59-68. PubMed ID: 26620043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer.
    McIntyre C; Byers S; Anson DS
    J Gene Med; 2010 Sep; 12(9):717-28. PubMed ID: 20683858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
    Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
    Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.
    Hassiotis S; Beard H; Luck A; Trim PJ; King B; Snel MF; Hopwood JJ; Hemsley KM
    Eur J Neurosci; 2014 Jun; 39(12):2139-50. PubMed ID: 25068161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
    Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
    Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).
    Meyer A; Kossow K; Gal A; Steglich C; Mühlhausen C; Ullrich K; Braulke T; Muschol N
    Hum Mutat; 2008 May; 29(5):770. PubMed ID: 18407553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.
    Perkins KJ; Muller V; Weber B; Hopwood JJ
    Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain.
    Jolly RD; Marshall NR; Perrott MR; Dittmer KE; Hemsley KM; Beard H
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):414-22. PubMed ID: 21175738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
    Mohammed EE; Snella EM; Rutz-Mendicino MM; Echevarria FD; Awedikian R; Whitley EM; Ellinwood NM
    Mol Genet Metab; 2012 Sep; 107(1-2):129-35. PubMed ID: 22867887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
    McIntyre C; Derrick Roberts AL; Ranieri E; Clements PR; Byers S; Anson DS
    Mol Genet Metab; 2008 Apr; 93(4):411-8. PubMed ID: 18248829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Engineered
    Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2014 Aug; 11(8):2928-34. PubMed ID: 24949884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.